ArticleEpidemiology and infection2026
Epidemiologic and economic impact of introducing a National Immunization Program for herpes zoster vaccination on the prevention of herpes zoster and postherpetic neuralgia in South Korea, an ageing society.
Article in Epidemiology and infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herpes zoster (HZ) and its complication, postherpetic neuralgia (PHN), disproportionately affect older adults and impose a considerable disease and economic burden. Although the Korea Disease Control and Prevention Agency recommends vaccination for adults aged ≥50 years, uptake remains limited. This study assessed the epidemiologic and economic impact of expanding vaccine coverage through inclusion of the live-attenuated zoster vaccine (ZVL) and the recombinant zoster vaccine (RZV) in the National Immunization Program (NIP). Using the incidence data from the Health Insurance Review and Assessment Service Open Statistics, along with vaccine effectiveness, coverage rates, and treatment cost estimates adjusted to 2025 values, we projected cases averted and associated cost savings. At the current 10% coverage, ZVL and RZV were estimated to prevent 36269 and 56681 HZ cases and 15988 and 20712 PHN cases, yielding societal cost savings of USD 78.47 million and USD 107.14 million, respectively. Expanding NIP coverage to 70% amplified benefits approximately sevenfold, yielding cost savings of USD 549.34 million (ZVL) and USD 749.98 million (RZV). These results demonstrate the substantial value of zoster vaccination and underscore the need for policy measures to improve vaccine coverage among older adults in South Korea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.